Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
72.87
-1.46 (-1.96%)
At close: Sep 12, 2025, 4:00 PM EDT
74.00
+1.13 (1.55%)
After-hours: Sep 12, 2025, 7:11 PM EDT
Corcept Therapeutics Employees
Corcept Therapeutics had 500 employees as of December 31, 2024. The number of employees increased by 148 or 42.05% compared to the previous year.
Employees
500
Change (1Y)
148
Growth (1Y)
42.05%
Revenue / Employee
$1,432,160
Profits / Employee
$264,022
Market Cap
7.68B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 500 | 148 | 42.05% |
Dec 31, 2023 | 352 | 53 | 17.73% |
Dec 31, 2022 | 299 | 61 | 25.63% |
Dec 31, 2021 | 238 | 2 | 0.85% |
Dec 31, 2020 | 236 | 30 | 14.56% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CORT News
- 3 days ago - FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 5 weeks ago - Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early - Seeking Alpha
- 6 weeks ago - Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update - Business Wire
- 7 weeks ago - Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 2 months ago - Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 2 months ago - Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators - Seeking Alpha
- 2 months ago - Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care - Business Wire